Objective: The aim of this study was to assess the association between the anthropometric/adiposity indices or ratios with the status of quality of life (QoL) in rheumatoid arthritis (RA) patients.
Methods: This study was carried out in the Rizgary Teaching Hospital in the Kurdistan Region of Iraq between 1 December 2021 and 31 March 2022. Seventy-five women with a mean value of 11.3 years' duration of disease were included in this study. The data relating to the demographic characteristics, disease activity score (DAS-28), biochemical measurements of the rheumatic profile, and anthropometric/adiposity indices and the ratios were included. The QoL of each patient was assessed using the WHOQOL-BREF.
Results: The mean ± SD of the age and duration of disease were 49.6± 12.0, and 11.3±8.4 year. 70 out of 75 (93.3%) patients have a DAS-28 score of >2.6. The median values of the transform scores of the WHOQOL-BREF domains were less than 50. There were significant inverse correlations between BMI, and waist-to-height ratio with physical activity (r = -0.167, p = 0.05, and r = -0.168, p = 0.05, respectively). Social domain was significantly and inversely correlated with waist-to-hip, estimated total body fat, and waist-adjusted weight index. A higher BMI and a lower hip index were associated significantly with a lower mean scores of physical health
Conclusion: In RA patients, obesity is frequently observed. Over-weight and obese patients had a significantly lower mean score of physical health.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350410 | PMC |
http://dx.doi.org/10.31138/mjr.230828.jaa | DOI Listing |
Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to amyloid-beta (Aβ) protofibrils, was formally evaluated as a treatment for early Alzheimer's disease in a phase 2 study (Study 201) and the phase 3 Clarity AD study. These trials both included an 18-month, randomized study (core) and an open-label extension (OLE) phase where eligible participants received open-label lecanemab for up to 30 months to date. Clinical (CDR-SB, ADAS-Cog14, and ADCS-MCI-ADL), biomarker (PET, Aβ42/40 ratio, and ptau181) and safety outcomes were evaluated.
View Article and Find Full Text PDFAlzheimer's disease pathophysiology is believed to involve various abnormalities, including those of amyloid beta (Ab) peptide and tau processing, inflammation, oxidative stress, and vascular risk factors. Aβ peptides exist in a dynamic continuum of conformational states from monomeric Aβ, to soluble progressively larger Aβ assemblies that include a range of low molecular weight oligomers to higher molecular weight protofibrils, and finally to insoluble fibrils (plaques). Various lines of evidence support the "amyloid hypothesis" that Aβ plays a central role in the pathogenesis of AD, and several immunotherapies have been developed to interact with this cascade in various different places which may reduce the number of soluble aggregates and insoluble Aβ fibrils deposited in the brain.
View Article and Find Full Text PDFBackground: Lecanemab is an approved anti-amyloid monoclonal antibody that binds with highest affinity to soluble Aβ protofibrils, which are more toxic than monomers or insoluble fibrils/plaque. In clinical studies, biweekly lecanemab treatment demonstrated a slowing of decline in clinical (global, cognitive, functional, and quality of life) outcomes, and reduction in brain amyloid in early Alzheimer's disease (AD). Herein, we describe the impact of lecanemab treatment on tau PET.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Stevenson University, Owings Mills, MD, USA.
Background: Most assisted living (AL) settings organize and provide opportunities for residents to participate in activities (e.g., exercise, music, arts and craft, cognitive activities, religious services, community outings).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: The progressive nature of dementia and the complex needs means that people living with dementia require tailored approaches to address their changing care needs over time. These include physical multimorbidity, psychological, behavioural, and cognitive symptoms and possible risks arising from these and helping family caregivers. However, provision of these interventions is highly variable between and within countries, partly due to uncertainty about their efficacy and scarce resources.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!